Cycle Pharmaceuticals

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

Retrieved on: 
Tuesday, May 5, 2020
Medical devices, Health, Research, Pharmaceutical, Science, Biotechnology, Medherant, Routes of administration, Health, Drug delivery, Transdermal, Adhesive, Cycle Pharmaceuticals, Medherant

Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize multiple products using the TEPI Patch technology.

Key Points: 
  • Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize multiple products using the TEPI Patch technology.
  • View the full release here: https://www.businesswire.com/news/home/20200504005647/en/
    Cycle will utilise Medherants proprietary TEPI Patch transdermal delivery technology to develop formulations that will address patients unmet needs such as dysphagia and dyskinesia, further expanding its pipeline.
  • Following TEPI Patch formulation development by Medherant, Cycle will be responsible for clinical development and registration, and will commercialise the products arising from this collaboration.
  • Medherant has built upon its founders world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch drug delivery technology.

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology

Retrieved on: 
Thursday, October 31, 2019
Medical devices, Health, Research, Pharmaceutical, Science, Biotechnology, Dosage forms, Pharmacology, Health sciences, Health, Zydis, Catalent, Tablet, ODT, Orally disintegrating tablet, Cycle Pharmaceuticals, Catalent

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent) (NYSE: CTLT), to develop innovative formulations targeting rare disease patients.

Key Points: 
  • Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent) (NYSE: CTLT), to develop innovative formulations targeting rare disease patients.
  • This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalents Zydis oral disintegrating tablet (ODT) and Zydis Ultra technologies.
  • The Zydis Ultra platform is the companys next generation ODT technology and allows for increased drug load and better taste masking to be incorporated into its proven Zydis ODT dosage form.
  • Working in partnership with Catalent to apply the Zydis technology to Cycles product pipeline will be life-changing for both patients and their caregivers.